FDA pulls authorization for AstraZeneca’s Covid antibody drug Evusheld
Published
The Food and Drug Administration has withdrawn emergency use authorization for AstraZeneca’s Covid-19 antibody cocktail Evusheld as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of omicron. The FDA had limited Evusheld’s use earlier this month for the same…
#astrazeneca #evusheld #fda #omicron #elililly